Incidence of post-operative nausea and vomiting after endoscopic bariatric and metabolic therapy procedures and the role of neurokinin-1 receptor antagonists: a retrospective cohort study

Beth A. VanderWielen,Andrew C. Storm,Darrel R. Schroeder,Juraj Sprung,Toby N. Weingarten
DOI: https://doi.org/10.1007/s00464-024-11327-3
2024-10-11
Surgical Endoscopy
Abstract:Both the transoral gastric reduction (TORe) and endoscopic sleeve gastroplasty (ESG) procedures are novel endoscopic bariatric and metabolic therapies (EBMT). Our practice has an aggressive approach to prophylaxis of postoperative nausea and vomiting (PONV) for EBMT cases, but there is divergence of practice regarding use of prophylactic neurokinin-1 receptor (NK-1) antagonists (aprepitant, fosaprepitant). Herein, we determined the incidence of PONV and its potential association with NK-1 antagonist administration following EBMT.
surgery
What problem does this paper attempt to address?